| Francisco J Cordero-gallardo, MD | |
|
Ext. Hermanas Davila, Marginal Pr #2, Edif. 1955 Suite G1, Bayamon, PR 00959 | |
| (787) 966-7500 | |
| (787) 966-7505 |
| Full Name | Francisco J Cordero-gallardo |
|---|---|
| Gender | Male |
| Speciality | Radiation Oncology |
| Experience | 10 Years |
| Location | Ext. Hermanas Davila, Marginal Pr #2, Bayamon, Puerto Rico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689091779 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | 21375 (Puerto Rico) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Caribbean Imaging And Radiation Treatment Center Inc | 4486782307 | 14 |
| Centro De Radioterapia Auxilio Mutuo Inc | 2365507068 | 6 |
News Archive
"Sri Lanka is making progress in the battle against mosquito-borne dengue fever, say health officials," IRIN reports.
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the granting of a pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA) and successful completion of its third pivotal Phase 3 registration trial (study 009) for immediate-release MoxDuo.
As the world grapples with a novel coronavirus pandemic, a new strain of swine flu that can trigger a pandemic has been reported.
The Society of Interventional Radiology has a long-term commitment to radiation safety, taking a leading role in measuring and assessing radiation dosage; developing educational programs on radiation safety, radiation protection and reduction of skin dosage; and promoting the safety of patients and health care professionals.
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
› Verified 3 days ago
| Entity Name | Centro De Radioterapia Auxilio Mutuo Inc |
|---|---|
| Entity Type | Part B Supplier - Radiation Therapy Center |
| Entity Identifiers | NPI Number: 1154379253 PECOS PAC ID: 2365507068 Enrollment ID: O20090212000390 |
News Archive
"Sri Lanka is making progress in the battle against mosquito-borne dengue fever, say health officials," IRIN reports.
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the granting of a pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA) and successful completion of its third pivotal Phase 3 registration trial (study 009) for immediate-release MoxDuo.
As the world grapples with a novel coronavirus pandemic, a new strain of swine flu that can trigger a pandemic has been reported.
The Society of Interventional Radiology has a long-term commitment to radiation safety, taking a leading role in measuring and assessing radiation dosage; developing educational programs on radiation safety, radiation protection and reduction of skin dosage; and promoting the safety of patients and health care professionals.
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
› Verified 3 days ago
| Entity Name | Caribbean Imaging And Radiation Treatment Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033183603 PECOS PAC ID: 4486782307 Enrollment ID: O20100513000145 |
News Archive
"Sri Lanka is making progress in the battle against mosquito-borne dengue fever, say health officials," IRIN reports.
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the granting of a pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA) and successful completion of its third pivotal Phase 3 registration trial (study 009) for immediate-release MoxDuo.
As the world grapples with a novel coronavirus pandemic, a new strain of swine flu that can trigger a pandemic has been reported.
The Society of Interventional Radiology has a long-term commitment to radiation safety, taking a leading role in measuring and assessing radiation dosage; developing educational programs on radiation safety, radiation protection and reduction of skin dosage; and promoting the safety of patients and health care professionals.
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
› Verified 3 days ago
| Entity Name | Precise Radiation Oncology Center Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033426614 PECOS PAC ID: 2961685482 Enrollment ID: O20110322000121 |
News Archive
"Sri Lanka is making progress in the battle against mosquito-borne dengue fever, say health officials," IRIN reports.
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the granting of a pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA) and successful completion of its third pivotal Phase 3 registration trial (study 009) for immediate-release MoxDuo.
As the world grapples with a novel coronavirus pandemic, a new strain of swine flu that can trigger a pandemic has been reported.
The Society of Interventional Radiology has a long-term commitment to radiation safety, taking a leading role in measuring and assessing radiation dosage; developing educational programs on radiation safety, radiation protection and reduction of skin dosage; and promoting the safety of patients and health care professionals.
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
› Verified 3 days ago
| Entity Name | Precise Radiosurgery Solutions Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437779907 PECOS PAC ID: 7618393133 Enrollment ID: O20200814000875 |
News Archive
"Sri Lanka is making progress in the battle against mosquito-borne dengue fever, say health officials," IRIN reports.
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the granting of a pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA) and successful completion of its third pivotal Phase 3 registration trial (study 009) for immediate-release MoxDuo.
As the world grapples with a novel coronavirus pandemic, a new strain of swine flu that can trigger a pandemic has been reported.
The Society of Interventional Radiology has a long-term commitment to radiation safety, taking a leading role in measuring and assessing radiation dosage; developing educational programs on radiation safety, radiation protection and reduction of skin dosage; and promoting the safety of patients and health care professionals.
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Francisco J Cordero-gallardo, MD Po Box 1589, Bayamon, PR 00960-1589 Ph: (787) 966-7500 | Francisco J Cordero-gallardo, MD Ext. Hermanas Davila, Marginal Pr #2, Edif. 1955 Suite G1, Bayamon, PR 00959 Ph: (787) 966-7500 |
News Archive
"Sri Lanka is making progress in the battle against mosquito-borne dengue fever, say health officials," IRIN reports.
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the granting of a pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA) and successful completion of its third pivotal Phase 3 registration trial (study 009) for immediate-release MoxDuo.
As the world grapples with a novel coronavirus pandemic, a new strain of swine flu that can trigger a pandemic has been reported.
The Society of Interventional Radiology has a long-term commitment to radiation safety, taking a leading role in measuring and assessing radiation dosage; developing educational programs on radiation safety, radiation protection and reduction of skin dosage; and promoting the safety of patients and health care professionals.
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
› Verified 3 days ago
Dr. Robert Rivera, Radiology Medicare: Accepting Medicare Assignments Practice Location: 1815 Road # 2 Km 11.7, Ct Radiology Complex Bldg, Bayamon, PR 00959 Phone: 787-780-9069 Fax: 787-780-2121 | |
Dr. Pedro E Diaz Ortiz, Radiology Medicare: Accepting Medicare Assignments Practice Location: Gallardo Towers, 201, Bayamon, PR 00961 Phone: 787-787-8029 Fax: 787-787-8029 | |
Francisco Jose Orobitg Brenes, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: Ct Radiology Complex, 1815 Carr 2, Bayamon, PR 00959 Phone: 787-780-9069 Fax: 787-778-4938 | |
Dr. Carlos Balsalobre Alonso, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1815 Road No 2 Km 11.7, Ct Radiology Complex, Bayamon, PR 00959 Phone: 787-780-9069 Fax: 787-780-2121 | |
Dr. Alberto Cerra Franco, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: Ext. Hnas Davila. Marginal Pr #2. Esq 3b, Edificio 1955. Suite G1, Bayamon, PR 00959 Phone: 787-966-7500 | |
Rafael Andres Vicens Rodriguez, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1710 Carr 2 # Int167, Condominio Gallardo Towers Suite 101, Bayamon, PR 00961 Phone: 787-785-8034 Fax: 787-787-8029 | |
Dr. Luisa Vanessa Marcial, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: Ext. Hnas Davila Marginal Carr. Pr #2, Edificio 1955 Suite G-1, Bayamon, PR 00959 Phone: 787-966-7500 Fax: 787-966-7505 |